DiLab Inventing the future of automated blood sampling

CMA Microdialysis AB (”CMA”) today announced that is has signed an agreement to acquire the assets of DiLab i Lund AB, for an undisclosed cash amount. DiLab is the pioneer and market leader in the field of Automated Blood Sampling (ABS) providing solutions to the Life Science Industry for over 20 years. The acquisition is expected to complement CMA’s portfolio of leading research solutions for use in drug discovery and development.

CMA is the industry leader providing microdialysis solutions for in vivo sampling and monitoring of tissues and organs. CMA’s unique products are used across the globe in early drug discovery, PK/PD, clinical research and routinely for monitoring critically ill patients in intensive care.

For more info, see press release